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Abstract
Objective—The economic implications of sedative choice in the management of patients receiving
mechanical ventilation are unclear because of differences in costs and clinical outcomes associated
with specific sedatives. Therefore, we aimed to determine the cost-effectiveness of the most
commonly used sedatives prescribed for mechanically ventilated critically ill patients.
Design, Setting, and Patients—Adopting the perspective of a hospital, we developed a
probabilistic decision model to determine if continuous propofol or intermittent lorazepam was
associated with greater value when combined with daily awakenings. We also evaluated the
comparative value of continuous midazolam in secondary analyses. We assumed that patients were
managed in a medical intensive care unit and expected to require ventilation for at least 48 hours.
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Model inputs were derived from primary analysis of randomized controlled trial data, medical
literature, Medicare reimbursement rates, pharmacy databases, and institutional data.
Main Results—We measured cost-effectiveness as costs per mechanical ventilator-free day within
the first 28 days after intubation. Our base-case probabilistic analysis demonstrated that propofol
dominated lorazepam in 91% of simulations and, on average, was both $6,378 less costly per patient
and associated with over three additional mechanical ventilator-free days. The model did not reveal
clinically meaningful differences between propofol and midazolam on costs or measures of
effectiveness.
Conclusion—Propofol has superior value compared to lorazepam when used for sedation among
the critically ill who require mechanical ventilation when used in the setting of daily sedative
interruption.
Keywords
cost-effectiveness; cost-benefit analysis (MeSH); critical illness (MeSH); respiration; artificial
(MeSH)
INTRODUCTION
Mechanical ventilation is the most common intervention delivered daily to tens of thousands
of patients in intensive care units (ICUs) worldwide. (1,2) The provision of pharmacological
sedation and analgesia to those receiving ventilation is an essential part of quality critical care
because adequate sedation can reduce patient anxiety, improve patient-ventilator synchrony,
and facilitate overall clinical care. (3,4)
Current clinical practice guidelines recommend the provision of either intermittent or
continuous lorazepam as the primary sedative for patients requiring prolonged ventilation and
continuous propofol or midazolam for patients requiring short-term (48–72 hours) ventilation.
(5) Although these and other sedatives have been compared in past studies, few have been
assessed rigorously with high-quality, randomized clinical trials that included outcomes such
as duration of ventilation and length of hospital stay. (6) To our knowledge, only two
randomized clinical trials evaluating sedation regimens have been published that also
incorporated daily trials of awakening from sedation, an intervention now widely utilized. (7,
8) Neither of these studies, one comparing midazolam to propofol and the other comparing
propofol to intermittent lorazepam, reported a survival advantage to any specific sedative
regimen. (7,8)
Given the lack of mortality differences among these three sedatives, other factors such as costs
and clinical outcomes like frequency of adverse events, duration of mechanical ventilation,
and length of stay could be useful in differentiating the value of these products that are part of
the $180 billion spent annually on critical care in the US. (7,9–11) Although propofol may
facilitate weaning when compared to lorazepam, it is significantly more costly than lorazepam
and is associated with significant hemodynamic and metabolic side effects. (12,13) Because
of these concerns, many practitioners use midazolam because it is perceived to have a
considerably shorter half-life than lorazepam and is less expensive than propofol. However,
accumulation of midazolam and its active metabolites is likely to occur in critically ill patients
potentially causing prolonged sedation. (14)
Because of the strong association between ICU length of stay and costs, identification of safe
and effective sedative options that can also reduce resource utilization during a time of changing
population demographics is important for policymakers and clinicians alike. (15,16) However,
we know of no formal economic analyses comparing sedatives in the setting of contemporary
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critical care practice. Therefore, we performed cost-effectiveness analysis comparing
continuous propofol and intermittent lorazepam for the sedation of critically ill adults with
secondary analyses including midazolam.
METHODS
Study design
We used a decision analysis model to compare the value of continuous propofol and
intermittent lorazepam in our base-case analysis (Figure 1). In secondary analyses, we
compared continuous midazolam to both propofol and lorazepam since they are the three most
commonly used sedatives in an ICU setting. (17) We did not include midazolam as part of the
primary analysis because of the lack of data on its direct comparison with lorazepam in the
setting of daily awakening from sedation. We assumed that if patients tolerated the sedative,
they then survived or died based on model inputs. Patients who experienced a sedative-
associated adverse event crossed over to the comparator sedative, accruing costs and effects
to the initial treatment while achieving the intended therapeutic effect with the second sedative.
We followed recommendations for the conduct of cost-effectiveness analyses whenever
possible, though with some notable departures due to the unique nature of the patient group
and interventions compared. (18) First, instead of the recommended societal perspective, we
conducted the analysis from the perspective of the hospital because prospective payment
reimbursement structures in place between hospitals and payors create incentives for providers
to minimize costs. Also, because there is no known long-term survival advantage to any
particular sedation protocol, we limited the time horizon to 28 days from the initiation of
mechanical ventilation. All costs were adjusted to 2007 US dollars using the Medical Care
component of the US Consumer Price Index. (19) Because of the short time horizon, costs were
not discounted.
Our primary data sources included original data from randomized controlled trials published
by Carson and colleagues, comparing propofol to intermittent lorazepam, and Kress, et al, who
randomized patients to propofol versus midazolam as well as to daily awakening trials versus
no awakening. (7,8) Patients were enrolled in these studies if they had an anticipated
requirement for mechanical ventilation of >48 hours and required significant amounts of
sedatives either in the form of continuous infusions or more than minimal doses of lorazepam.
We also included data from what we felt were relevant, high quality studies (Table 1).
Patient population and process of care characteristics
Base-case patient—We modeled the base-case patient on the cohort composition reported
in the Carson, et al study in which patients were 55 years old and managed in a medical intensive
care unit. We also assumed patients would receive screening daily for the appropriateness of
spontaneous breathing trials in anticipation of ventilator liberation and that daily awakening
trials were performed in which sedatives were stopped each morning until patients could follow
simple commands.
Sedative and analgesic dosing—Estimates of sedative and analgesic dosing were based
on original data from the Carson and Kress studies (Table 1). Sedative doses were targeted to
achieve a Ramsay sedation score of 3 (responds to command only) or 4 (asleep but with a brisk
response to a light glabellar tap or loud sound) in the Kress study and 2 (cooperative, oriented,
and tranquil) or 3 (responds to command only) in the Carson study. (20) The protocols for
dosing continuous propofol, continuous midazolam, intermittent lorazepam, and morphine
have been described elsewhere. (7,8)
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Adverse events—We recognized that the sedative initially prescribed might either provide
inadequate sedation or lead to untoward adverse effects, necessitating crossover to the
comparator drug. For the base-case analysis, we assumed that patients who did not tolerate
propofol crossed over to lorazepam and vice versa. In secondary analyses in which midazolam
was included, we assumed that propofol-intolerant patients received midazolam and vice versa.
Expenses related to the adverse effects of sedatives are shown in Table 1.
Overall base-case crossover rates (6% for propofol and 8% for lorazepam) were based on
Carson, et al. We assumed that the failure rate for midazolam would approximate that of
lorazepam (8%). Adverse effects of propofol (inadequate sedation, hypertriglyceridemia,
pancreatitis, and hemodynamic instability) as well as lorazepam (inadequate sedation and
metabolic acidosis related to the drug’s propylene glycol carrier) and midazolam (inadequate
sedation) were included in the model and their input values in sensitivity analyses defined by
ranges reported in the relevant literature. (12,13,21,22)
Equivalence of comparisons between midazolam and propofol recipients—Our
model assumed that clinical outcomes (though not drug costs) of those receiving midazolam
were equivalent to propofol recipients based on the study by Kress, et al. (8) This study reported
no significant differences in clinical characteristics or outcomes including length of stay and
mortality between propofol and midazolam recipients whom received daily awakenings from
sedation. We independently verified this equivalency through our own statistical analyses of
the original Kress, et al dataset (not shown).
Clinical effects
We expressed our results in terms of costs and both mechanical ventilator-free days and
mechanical ventilator-free survival. Mechanical ventilator-free days were defined as the total
number of days free from mechanical ventilation within the first 28 days from the time of
intubation. Mechanical ventilator-free survival was defined as the total number of days free
from mechanical ventilation within the first 28 days from the time of intubation for hospital
survivors. The validity and utility of using ventilator-free days as an outcome in critical care
research has been described elsewhere. (23)
Hospital Outcomes—Because there is no proven survival difference between those
receiving propofol, lorazepam, or midazolam, we assumed that ICU and hospital mortality
were equivalent in all groups. Further, we assumed that the average duration of hospitalization
was equal for all groups based on the work of Carson, et al. The primary differences among
groups were related to length of ICU stay and duration of mechanical ventilation, outcomes
that differed based on ICU survivorship status. (7,8)
Costs—Only direct costs were incorporated in the model (Table 1). Although costs were
estimated using a variety of sources relevant to different stakeholders in this issue, we
incorporated published costs from national database sources when possible to maximize the
ability to generalize our results. We held unit costs static in the base-case probabilistic model,
though varied important cost variables in one-way sensitivity analyses.
Pharmacy: Drug prices were representative of 2007 national wholesale acquisition costs
(WACs) to provide better estimates of the actual cost borne by a hospital system compared to
the use of average wholesale prices. (24) We have included in our one-way sensitivity analyses
wide variance in drug costs to account for the potential diversity in actual costs encountered
by different providers. In general, the cost range examined in sensitivity analyses represents
+/−50% of the WAC with the exception that propofol’s upper bound corresponded to the WAC
for the branded product Diprivan™.
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Hospitalization: Daily ICU costs were based on the medical subset of patients drawn from a
larger national sample of 51,000 critically ill ventilated patients. (25) A lower range for ICU
cost in sensitivity analyses was the daily Medicare reimbursement rate for DRG 565
(mechanical ventilation for ≥96 hours). This was calculated by dividing the average DRG
payment ($28,837) by its corresponding mean length of stay (15.8 days). The upper range was
established by inflating the base-case daily ICU cost by 50%. Daily hospital ward costs were
based on MedPAR analyses of general ICU patients utilizing the Russell equation and cost
ranges used in sensitivity analyses were calculated by adding and subtracting 50% of the base-
case cost. (26) We included professional costs for the primary treating physician based on
current procedural terminology (CPT) codes and Medicare fee schedules, varying these costs
+/− 50% in sensitivity analyses. (27)
Probabilistic and Sensitivity Analyses
Because of the uncertainty in some of our base-case estimates, we elected to present our main
results based on probabilistic analyses generated using Monte Carlo simulation rather than
deterministic analyses that would have generated only point estimates. Specifically, for
probabilistic analyses, we first specified distributions for all input variables. We used gamma
distributions to model continuous variables and beta distributions to model dichotomous
variables (Table 2). The sample size (n= 132) used to calculate standard errors for probability
distributions was based on number of patients enrolled in the Carson, et al study. (7) Next,
average values of 1,000 separate simulations were reported along with cost-effectiveness
scatterplots. We also performed one-way and two-way sensitivity analyses to understand how
varying data inputs across pre-specified ranges (not distributions) could affect point estimates
of costs and effectiveness (Table 2). We used Excel (Microsoft) to develop the cost-
effectiveness analysis and Stata 9 (Stata; College Station, TX) for statistical analyses. These
analyses were judged exempt from formal IRB review by 45 CFR 46.101(b) because they
utilized previously collected, completely de-identified data.
RESULTS
In our base-case scenario, we found that propofol clearly dominated lorazepam based on its
comparatively lower overall costs ($45,631 vs $52,009) and greater effects, as quantified by a
gain of over three mechanical ventilator-free days (Table 2). In fact, propofol was less costly
or more efficacious in 94% and 90% of 1,000 simulations performed, respectively. In 91% of
simulations, propofol was both less costly and more efficacious.
Our secondary probabilistic analyses demonstrated that allowing propofol crossover to
midazolam instead of lorazepam in the setting of associated adverse events produced results
similar to the base-case (Table 2). Additionally, midazolam’s dominance of intermittent
lorazepam in direct comparison was consistent with the base-case analysis comparing propofol
to lorazepam. We found no meaningful differences between propofol and midazolam on costs
or effectiveness, however. The superimposed clustering of 1,000 comparative simulations
shown in Figure 2 and Figure 3 demonstrates that the true difference in value between the two
is unlikely to be clinically important.
Although we found little evidence to favor propofol over midazolam, we were interested in
exploring how robust our analyses were when comparing the two sedatives. Table 3 shows the
results of varying average duration of ventilation by group since this variable appeared to have
the greatest impact on sedative value in our model. Assuming clinical, not cost, equivalence
in these two sedatives there is a minor cost advantage per case seen with midazolam ($319)
relative to propofol. However, varying the difference in average ventilation duration by as little
as one day had important effects on costs and ventilator-free days. For example, if propofol
use is actually associated with one fewer day of ventilation relative to midazolam, overall
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comparative costs are $6,286 less with an average gain of 0.354 ventilator-free days. The
opposite effect occurred when we assumed that midazolam was associated with a one day
reduction in ventilator days compared to propofol.
Across the range of one-way sensitivity analyses, propofol use was associated not only with
gains in the number of ventilator-free days but also with lower costs in comparison with
lorazepam as shown in the tornado diagram (Figure 4). The only realistic scenario in which
lorazepam was more effective than propofol was when the propofol to lorazepam ratio of
ventilator days exceeded 1.5. For example, assuming propofol use resulted in an average
ventilation duration of 6 days, lorazepam use would theoretically result in greater numbers of
ventilator-free days only when the average duration of ventilation for this group was less than
4 days (that is, 6 days/1.5) owing to the comparatively longer duration of ventilation and ICU
care among lorazepam survivors of ventilation. Drug and physician costs had a minor impact
on overall costs and effects in these sensitivity analyses.
DISCUSSION
Clinicians’ practice of prescribing and monitoring the use of sedatives among the hundreds of
thousands of patients receiving mechanical ventilation in ICUs annually has profound
implications. Sedation use is intimately associated not only with patient comfort but the
duration of mechanical ventilation, incidence of delirium, and overall resource utilization.
(28,29) Because of the comparatively high cost of each ventilator day and the observation that
many ICU patients may generate a net financial loss primarily related to ICU length of stay,
healthcare providers should search preferentially for interventions and therapies designed to
decrease days of ventilation. (26)
Given the advancing age of the US population and expected increase in critical care utilization
in the coming decades, planning for future needs in a climate of potential economic restraint
and resource limitation is crucial in the resource-intensive ICU setting. (30) Therefore, the
results of our economic analysis have contemporary importance for physicians, pharmacists,
administrators, and policymakers and add to the relatively small body of critical care cost-
effectiveness research. (15,31)
We believe that there is a common perception that propofol use is inherently expensive in
comparison to lorazepam and that favoring the latter in routine clinical practice may conserve
resources. (32) However, our analyses show that propofol has superior value when compared
to lorazepam and may have equivalent value to midazolam when daily interruption of sedation
occurs. We found that in nearly all scenarios and simulations, the use of propofol for sedation
is associated with lower overall costs and greater ventilator-free days when compared to
lorazepam. In fact, despite lorazepam’s considerably lower pharmacy unit cost, its use results
in additional days of mechanical ventilation. This in turn, increases the risk of ventilator-
associated pneumonia and other costly and morbid time-dependent hazards of critical care.
(33) We feel that this and other studies suggest that using lorazepam for the sedation of
mechanically ventilated patients who require more than minimal amounts of sedation conveys
few advantages. (29)
It is difficult to compare our work to the existing medical literature examining sedatives from
an economic perspective because these past studies were undertaken before clinical practice
advanced to include daily awakenings from sedation and spontaneous breathing trials. It is
likely that without daily interruption of continuous infusions, the difference in effectiveness
between propofol or midazolam and lorazepam would be less. Additional limitations of past
work include incorporation of medication costs instead of overall hospitalization costs, data
collection within different countries during times when comparative exchange rates are
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difficult to now appreciate, consideration of only short-term sedation, lack of sensitivity
analysis use to examine the impact of data input uncertainty, and inclusion of propofol costs
based on its more expensive branded formulation. (32,34–37)
Because of the ubiquity of sedative use in the ICU setting, we believe that our results underscore
the importance of determining whether clinically important differences exist among commonly
used sedatives with respect to mechanical ventilation-free days and length of stay. For example,
assuming equivalence in ventilator-free days and length of stay, a hospital treating 1,000
ventilated patients annually could theoretically save over $300,000 by using midazolam instead
of propofol. However, if midazolam use was actually associated with even one extra ICU day,
the balance would swing in the opposite direction, with a comparative annual opportunity loss
of over $2.5 million. Even an extra hospital ward day would represent over $385,000 in
additional costs. The tens of thousands of ventilated patients managed daily magnify the
potential implications of these unclear outcomes differences. Interestingly, our analyses
suggest that even newer, more expensive sedatives such as dexmedetomidine (average cost
$300–500 per day) are likely to have favorable value in comparison to other sedatives if their
primary or adjunctive use is associated with a comparative reduction in either ICU or hospital
length of stay by as little as one day. (38)
Our study has limitations that are important to highlight. First, we have utilized data from
different sources. Although we gathered these data from what we felt were the highest quality
studies, there may be bias inherent in this practice. Another factor worth considering is our use
of data from two different trials to estimate values for key variables in the model for propofol
and midazolam. Even though we performed our own analyses of these studies’ primary data
to establish that no significant differences existed between these groups’ clinical outcomes (not
shown), there could nonetheless be an underappreciated difference. Still, when we applied
various ranges of input variables and outlined assumptions that seemed reasonable given the
absence of a larger comparative randomized trial, our results were upheld. Third, our metric
of cost per mechanical ventilator-free day is relatively novel in the cost-effectiveness literature.
However, its use as an outcome measure in critical care is increasingly accepted and practical
considering its salutary effect on sample sizes in clinical trials. (23) Also, because the impact
of transitioning from one sedative to a less expensive alternative as the summative days of
ventilation accrue is unknown, we were unable to include this strategy in our model. Also, we
were unable to incorporate the independent effect of sedative-associated delirium because of
source data limitations. (29) Finally, because the effect of different sedative regimens on long-
term outcomes and costs is unknown, our model was focused on acute care outcomes. Although
we believe our model is helpful for clinicians caring for typical critically ill patients, it is
intended to augment and not replace clinical judgment in decision-making.
Conclusion
In conclusion, continuous propofol used for sedation among those receiving mechanical
ventilation have significantly lower overall costs and a greater number of ventilator-free days
in comparison to intermittent lorazepam. The routine use of lorazepam as the primary sedative
choice should be discouraged based on its comparatively poor value in this particular critical
care setting. Contemporary, adequately powered comparative studies of common sedatives
including propofol and midazolam are also needed to determine if either has a comparative
economic advantage.
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Figure 1. Decision Model
This is a simplified version of the decision model used in analyses. In this model, patients
ventilated for at least 48 hours could either receive propofol or lorazepam for sedation.
Progression through the decision tree over the course of the succeeding 28 days examined was
determined by probabilities defined in Table 1.
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Figure 2. Scatterplot of probabilistic analyses comparing costs and effects
These scatterplots depict the results of 1,000 simulations during which important clinical
variables were allowed to vary simultaneously within predefined distributions (see Methods).
In contrast to Figure 4, the axes represent the actual (not incremental) costs and effects of each
separate trial. This figure demonstrates near duplication of propofol (blue circles) costs and
effects for midazolam (yellow circles), though little overlap of lorazepam with either of these
groups—emphasizing the dominance of propofol and midazolam over lorazepam (pink
circles).
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Figure 3. Scatterplot of probabilistic analyses comparing incremental costs and effects
These scatterplots graph the results of 1,000 simulations during which important clinical
variables were allowed to vary simultaneously within predefined distributions (see Methods).
The x axis represents the incremental difference in mechanical ventilator-free days by group
(propofol – lorazepam in Graph A, midazolam – lorazepam in Graph B, and propofol –
midazolam in Graph C). The y axis represents incremental costs calculated in a similar fashion.
The clustering of simulation results in the lower right quadrant in Graphs A and B demonstrates
the comparative dominance of propofol and midazolam over lorazepam. The clustering of
analyses at the intersection of the axes in Graph C suggests that there is little evidence that
clinically or economically important differences exist between propofol and midazolam.
Cox et al. Page 13













Figure 4. Tornado diagram comparing cost differences between lorazepam and propofol
The length of the horizontal bars corresponds to the difference in average costs between
lorazepam and propofol groups over the range specified for variables of interest depicted on
the y axis. The vertical line transecting the bars represents the cost difference between
lorazepam and propofol in the point-estimate (non-probabilistic) base-case analysis. The
horizontal line at the top of the figure represents the range of values over which propofol’s cost
is less than that of lorazepam. There were fewer mechanical ventilator-free days in all ranges
and scenarios with the exception of a propofol to lorazepam ratio of mechanical ventilation
duration >1.5 (for example, 6 propofol ventilator days to 4 lorazepam ventilator days). The
grey bar and horizontal arrow depict this gain in lorazepam-associated mechanical ventilator-
free days.
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Table 1
Input Variables and Sources for Base-Case Scenario and Ranges for Sensitivity Analyses
Variable Base-Case
Estimate*





Medication utilization during mechanical ventilation
Propofol, mg/day 2,773 (290) Gamma 949–4,347 (7)
Lorazepam, mg/day 12 (2) Gamma 4–23 (7)
Midazolam, mg/day 54 (6) Gamma 34–84 (8)
Morphine, mg/day
  Propofol base-case 71 (14) Gamma 16–100 (7)
  Lorazepam recipient 25 (5) Gamma (7)
  Midazolam recipient 42 (5) Gamma 14–80 (8)
Medication failure leading to crossover†
Propofol
  Inadequate sedation 4% (3%) Beta 0–25% (7)
  Hypertriglyceridemia‡ 1% (1%) Beta 0–15% (12)
  Pancreatitis‡ 0% (1%) Beta 0–10% (12)
  Hemodynamic instability 1% (1%) Beta 0–10% (12)
Lorazepam (7)
  Inadequate sedation 8% (3%) Beta 0–25%
  Metabolic acidosis 0% (1%) Beta 0–5%
Hospital mortality
Propofol 37% (6%) Beta 5–75% (7, 8)
  ICU during mechanical ventilation 64%
  ICU after extubation 12%
  Hospital ward after ICU discharge 24%
Lorazepam 37% (6%) Beta 5–75% (7)
  ICU during mechanical ventilation 75%
  ICU after extubation 4%
  Hospital ward after ICU discharge 21%
Length of care
Ventilator days Gamma (7, 8)
  Propofol, all patients 6 (2)
    Propofol survivor 4 (2) 2–21
    Propofol decedent 7 (2) 2–21
  Lorazepam, all patients 8 (2)
    Lorazepam survivor 9 (2) 2–21
    Lorazepam decedent 7 (2) 2–21
ICU length of stay Gamma (7, 8)
  Propofol survivor 9 (2) 5–28
  Propofol decedent 9 (2) 5–28
  Lorazepam survivor 12 (2) 7–28
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Variable Base-Case
Estimate*




  Lorazepam decedent 9 (2) 5–28
Hospital length of stay 18 (3) Gamma 10–30 (7, 8)
Additional ICU days with mechanical ventilation for complications
  Pancreatitis 2 Fixed 0–5 Assumption
  Metabolic acidosis 1 Fixed 0–2 Assumption
Costs
Medications
Propofol (10mg/mL; 100mL) $22.77 Fixed $11.37–$60.77 (24)
Lorazepam (2mg single injection) $1.82 Fixed $0.91–$7.28 (24)
Midazolam (5mg/mL) $1.21 Fixed $0.60–$7.37 (24)
Morphine (2mg single injection) $1.03 Fixed $0.80–$3.70 (39)
Other
Serum triglyceride level $7.90 Fixed $4–$12 Institutional data¶
Serum lipase level $7.24 Fixed $4–$18 Institutional data¶
Plastic tubing for infusion $5.50 Fixed $2–$8 Institutional data¶
CT of abdomen & pelvis with
contrast
$312 Fixed $156–$468 (27)
Intensive care unit (25, 26, 40)
Mechanical ventilation, day 1 $6,325 Fixed $1,825–$9,488
Mechanical ventilation, day 2 $5,076 Fixed $1,825–$7,614
Mechanical ventilation, ≥ day 3 $4,431 Fixed $1,825–$6,647
No mechanical ventilation, day $3,311 Fixed $1,825–$4,967
Hospital
Hospital ward, day $1,261 Fixed $631–$1,892 (26, 40)
Physician** (27)
ICU care/day, intubated $246.26 Fixed $123.13–$369.39
ICU care/day, extubated $76.81 Fixed $38.31–$115.22
Hospital ward care/day $54.04 Fixed $27.02–$81.06
CT=computerized tomography, hr=hour, ICU=intensive care unit, kg=kilogram, mcg=microgram, mg=milligram, mL=milliliter Propofol and midazolam
assumed to have clinical equivalence with the exceptions of side effect profile (assumed to mirror lorazepam) and costs.
*
Number is parentheses represents standard error. For point estimates presented as percentages, the sample size was 132 (64 in lorazepam group and 68
in propofol group).
†
Costs were added for propofol recipients who developed hypertriglyceridemia (two extra serum triglyceride levels) and propofol-associated pancreatitis
(daily lipase level while in the ICU, one abdomen and pelvis computerized tomography with and without contrast, and two extra ICU days with ventilation).
Lorazepam recipients who developed an associated metabolic acidosis were assumed to require one extra ventilator day.
‡
Hypertriglyceridemia was defined as serum triglyceride level >500mg/dL while pancreatitis was defined as either serum amylase ≥125 IU/L or lipase
≥60 IU/L.
¶
Based on costs from Duke University Medical Center.
**
We assumed ICU day one required >104 minutes of critical care time (CPT 99291 + 99292), other ICU days with intubation required 30-74 minutes
of critical care time (CPT 99291), and both post-extubation ICU care (CPT 99233) and hospital ward care (CPT 99232). (27)
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